KR101368130B1 - Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물 - Google Patents

Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물 Download PDF

Info

Publication number
KR101368130B1
KR101368130B1 KR1020127012503A KR20127012503A KR101368130B1 KR 101368130 B1 KR101368130 B1 KR 101368130B1 KR 1020127012503 A KR1020127012503 A KR 1020127012503A KR 20127012503 A KR20127012503 A KR 20127012503A KR 101368130 B1 KR101368130 B1 KR 101368130B1
Authority
KR
South Korea
Prior art keywords
methyl
mmol
fluoro
pyran
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127012503A
Other languages
English (en)
Korean (ko)
Other versions
KR20120082927A (ko
Inventor
안나 벨렌 베니토 콜라도
누리아 디아즈 부에조
알마 마리아 지메네즈-아구아도
셀리아 라푸엔테 블랑코
마리아 안젤레스 마르티네즈-그라우
콘셉시온 페드레갈-테르세로
미구엘 앤젤 톨레도 에스크리바노
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20120082927A publication Critical patent/KR20120082927A/ko
Application granted granted Critical
Publication of KR101368130B1 publication Critical patent/KR101368130B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020127012503A 2009-11-16 2010-11-12 Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물 Expired - Fee Related KR101368130B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382245.0 2009-11-16
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27
US61/298,628 2010-01-27
PCT/US2010/056449 WO2011060217A1 (en) 2009-11-16 2010-11-12 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (2)

Publication Number Publication Date
KR20120082927A KR20120082927A (ko) 2012-07-24
KR101368130B1 true KR101368130B1 (ko) 2014-02-27

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127012503A Expired - Fee Related KR101368130B1 (ko) 2009-11-16 2010-11-12 Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물

Country Status (18)

Country Link
US (1) US20120214784A1 (enExample)
EP (1) EP2501704B1 (enExample)
JP (1) JP5723381B2 (enExample)
KR (1) KR101368130B1 (enExample)
CN (1) CN102666550B (enExample)
AU (1) AU2010319400B2 (enExample)
BR (1) BR112012011710A2 (enExample)
CA (1) CA2781041C (enExample)
DK (1) DK2501704T3 (enExample)
EA (1) EA020391B1 (enExample)
ES (1) ES2436241T3 (enExample)
HR (1) HRP20130969T1 (enExample)
MX (1) MX2012005690A (enExample)
PL (1) PL2501704T3 (enExample)
PT (1) PT2501704E (enExample)
RS (1) RS53017B (enExample)
SI (1) SI2501704T1 (enExample)
WO (1) WO2011060217A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388468B (es) 2009-12-04 2025-03-20 Sunovion Pharmaceuticals Inc Compuestos multicíclicos y métodos de uso de los mismos.
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
AR105821A1 (es) * 2015-09-09 2017-11-15 Lilly Co Eli COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
MY199446A (en) 2016-07-29 2023-10-28 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
RU2019106494A (ru) 2016-08-10 2020-09-14 Байер Кропсайенс Акциенгезельшафт Замещенные 2-гетероциклил-имидазолил-карбоксамиды в качестве средств для борьбы с вредителями
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sumitomo Pharma America, Inc. Methods of treating schizophrenia
WO2018160547A1 (en) * 2017-03-02 2018-09-07 Eli Lilly And Company Compounds useful for inhibiting ror-gamma-t
SI3589638T1 (sl) 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
MY208150A (en) 2018-02-16 2025-04-18 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
JP7781768B2 (ja) 2020-04-14 2025-12-08 スミトモ・ファーマ・アメリカ・インコーポレイテッド 神経学的および精神障害の治療方法
MX2023002269A (es) 2020-08-26 2023-05-16 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos.
CA3251050A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
BRPI0509377A (pt) * 2004-03-29 2007-09-11 Pfizer compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1890696A4 (en) * 2005-06-02 2010-05-05 Janssen Pharmaceutica Nv Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, pp. 3778-3782 (2008-05-16) *

Also Published As

Publication number Publication date
JP2013510870A (ja) 2013-03-28
RS53017B (sr) 2014-04-30
AU2010319400A1 (en) 2012-06-07
JP5723381B2 (ja) 2015-05-27
KR20120082927A (ko) 2012-07-24
PT2501704E (pt) 2013-12-05
WO2011060217A1 (en) 2011-05-19
EP2501704A1 (en) 2012-09-26
EA201290355A1 (ru) 2012-10-30
PL2501704T3 (pl) 2014-02-28
MX2012005690A (es) 2012-06-13
EA020391B1 (ru) 2014-10-30
CN102666550B (zh) 2015-07-15
US20120214784A1 (en) 2012-08-23
CN102666550A (zh) 2012-09-12
CA2781041A1 (en) 2011-05-19
ES2436241T3 (es) 2013-12-27
DK2501704T3 (da) 2013-10-14
SI2501704T1 (sl) 2013-11-29
HRP20130969T1 (hr) 2013-11-22
CA2781041C (en) 2015-01-06
BR112012011710A2 (pt) 2016-03-01
EP2501704B1 (en) 2013-09-18
AU2010319400B2 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
KR101368130B1 (ko) Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물
KR101363830B1 (ko) Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물
WO2022229061A1 (en) Furoindazole derivatives as antagonists or inhibitors of gpr84
CN117642389A (zh) 一种哌啶衍生物及其药物组合物、制备方法和用途
HK1169988B (en) Spiropiperidine compounds as orl-1 receptor antagonists
BR112012012150A2 (pt) compostos spiro piperidina como antagonistas de recep-tor orl-1
TW200524608A (en) Therapeutic agents

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180207

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190208

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20200213

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210221

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210221